Featured Research

from universities, journals, and other organizations

Heart Rate-lowering Drug Improves Exercise Capacity In Patients With Stable Angina

Date:
November 4, 2008
Source:
University of Montreal
Summary:
An analysis of the data from treadmill exercise tests shows that patients who were treated with ivabradine in addition to a beta blocker demonstrated a threefold improvement in total exercise duration at four months compared to those being treated with standard doses of beta blocker alone.

Results from a late-breaking clinical trial, presented at the 2008 Canadian Cardiology Congress (CCC) in Toronto, show for the first time that combining the pure heart rate reduction medication ivabradine to current treatments of patients with stable angina improves their exercise capacity.

Related Articles


The study involved almost 900 patients from Canada and internationally with documented coronary artery disease and a history of stable angina. The objective was to determine if treatment with ivabradine could improve exercise capacity in these patients beyond what was previously achieved with standard treatments. Patients received either ivabradine 5 mg bid for two months (increased to 7.5 mg bid in 87.5 percent of patients for an additional two months) or placebo for four months in addition to their current beta blocker background therapy (atenolol 50 mg daily).

"Our findings confirm that adding ivabradine over and above the standard of care achieves increases exercise tolerance," said Dr. Jean-Claude Tardif, the study's lead investigator, a professor of medicine at the Universitι de Montrιal and director of the Montreal Heart Institute Research Centre.

"For patients who have stable angina the results are very encouraging, particularly because of tolerability concerns with higher doses of beta blockers. As a result patients are often not achieving optimal heart rate reduction on standard therapy alone," adds Dr. Tardif.

An analysis of the data from treadmill exercise tests shows that patients who were treated with ivabradine in addition to a beta blocker (n=441) demonstrated a threefold improvement in total exercise duration at four months compared to those being treated with standard doses of beta blocker alone.

After four months of treatment, the ivabradine and beta blocker combination was associated with a mean heart rate reduction of nine beats per minute (bpm) compared to one bpm in patients remaining on beta blockers alone. Patients receiving the ivabradine and beta blocker combination also had considerable improvements in symptoms and ischemia as measured by time to limiting angina, time to angina onset, and time to 1-mm ST-segment depression.

Ivabradine is not yet available for clinical use in Canada.

About Coronary Artery Disease

Coronary artery disease (CAD) is the most common manifestation of cardiovascular disease. It refers to the hardening and shrinking of the coronary arteries (atherosclerosis) which leads to diminished blood flow and reduces oxygen supply to the heart muscle (ischemia). The lack of oxygen supply to the heart muscle may cause angina (heart pain). If the coronary artery becomes completely blocked, a whole section of the heart muscle is deprived of oxygen and dies, resulting in a myocardial infarction (MI) or heart attack. Coronary artery disease is a progressive silent disease that very often is unobserved until the first symptoms of ischemia or MI occur. Although the prognosis of patients with CAD has been greatly improved by advances in cardiovascular treatment, it is still the first cause of death.

Cardiovascular disease accounts for the death of more Canadians than any other disease. In fact, in Canada someone dies every seven minutes from it. According to the latest statistics available from Statistics Canada, in 2004 cardiovascular disease accounted for close to one third of all deaths in Canada (more than 72,000 deaths).

Heart rate and CAD

Heart rate is a major determinant of oxygen consumption and can precipitate most episodes of ischemia, both symptomatic and silent. Consequently, lowering the heart rate in patients with CAD reduces the heart's need for oxygen. A number of epidemiological studies have shown that heart rate is a strong and independent predictor of cardiovascular events in a wide range of patients, including those with CAD and post-myocardial infarction. This risk seems to become particularly evident with heart rate above 70 bpm.


Story Source:

The above story is based on materials provided by University of Montreal. Note: Materials may be edited for content and length.


Cite This Page:

University of Montreal. "Heart Rate-lowering Drug Improves Exercise Capacity In Patients With Stable Angina." ScienceDaily. ScienceDaily, 4 November 2008. <www.sciencedaily.com/releases/2008/10/081030111003.htm>.
University of Montreal. (2008, November 4). Heart Rate-lowering Drug Improves Exercise Capacity In Patients With Stable Angina. ScienceDaily. Retrieved December 22, 2014 from www.sciencedaily.com/releases/2008/10/081030111003.htm
University of Montreal. "Heart Rate-lowering Drug Improves Exercise Capacity In Patients With Stable Angina." ScienceDaily. www.sciencedaily.com/releases/2008/10/081030111003.htm (accessed December 22, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, December 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Touch-Free Smart Phone Empowers Mobility-Impaired

Touch-Free Smart Phone Empowers Mobility-Impaired

Reuters - Innovations Video Online (Dec. 21, 2014) — A touch-free phone developed in Israel enables the mobility-impaired to operate smart phones with just a movement of the head. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Earthworms Provide Cancer-Fighting Bacteria

Earthworms Provide Cancer-Fighting Bacteria

Reuters - Innovations Video Online (Dec. 21, 2014) — Polish scientists isolate bacteria from earthworm intestines which they say may be used in antibiotics and cancer treatments. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Existing Chemical Compounds Could Revive Failing Antibiotics, Says Danish Scientist

Existing Chemical Compounds Could Revive Failing Antibiotics, Says Danish Scientist

Reuters - Innovations Video Online (Dec. 21, 2014) — A team of scientists led by Danish chemist Jorn Christensen says they have isolated two chemical compounds within an existing antipsychotic medication that could be used to help a range of failing antibiotics work against killer bacterial infections, such as Tuberculosis. Jim Drury went to meet him. Video provided by Reuters
Powered by NewsLook.com
Hugging It Out Could Help You Ward Off A Cold

Hugging It Out Could Help You Ward Off A Cold

Newsy (Dec. 21, 2014) — Carnegie Mellon researchers found frequent hugs can help people avoid stress-related illnesses. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins